Snapshot · Amgen Inc. (AMGN)

Data as of 2026-09-01T11:00:17.421Z

Fundamentals check

Market cap

$232.0B

P/E (TTM)

26.5

Gross margin

72.7%

Net margin

22.9%

ROE

89.3%

R&D / revenue

20.0%

Dividend yield

2.3%

FCF yield

4.4%

Latest dividend: $2.52/share (ex-date 2026-08-21, quarterly)

Summary

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

How it makes money

Revenue mix, latest fiscal year

• Other Products20.6%
• Prolia12.5%
• Repatha8.5%
• Otezla6.4%
• ENBREL6.3%
• EVENITY5.9%

Recent Events

• 2026-08-29T11:45:01.000Zneutral

  Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

  可能与对比分析相关，但未证实因果关系，需结合多方信息评估投资潜力。

  Source: fool.com

• 2026-08-24T11:40:27.000Zpositive

  Amgen Touches 52-Week High: Buy, Sell or Hold the Stock?

  可能与AMGN近期创新高相关，提示投资者对股价走势保持关注，具体决策需结合其他因素。

  Source: zacks.com

• 2026-08-24T07:21:00.000Zneutral

  Is AMGN Overvalued? DCF Says Worth $296

  恰逢DCF分析报道，提供价值评估参考，但不构成明确买卖建议，需结合市场与基本面判断。

  Source: gurufocus.com

• 2026-08-24T03:56:04.000Zneutral

  Amgen Inc. $AMGN Shares Sold by Allstate Corp

  或有助于了解机构持仓动态，未直接指示价格方向，需结合其他数据分析。

  Source: defenseworld.net

• 2026-08-23T04:00:06.000Znegative

  Beutel Goodman & Co Ltd. Sells 128,742 Shares of Amgen Inc. $AMGN

  恰逢大额减持报道，可能与投资者情绪及供需变化相关，但不表示因果关系。

  Source: defenseworld.net

• 2026-08-19T00:00:00.000Zpositive

  Price move: AMGN rose 4.0%

  AMGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-05T00:00:00.000Zpositive

  Price move: AMGN rose 4.6%

  AMGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-28T00:00:00.000Zpositive

  Price move: AMGN rose 4.5%

  AMGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-02T00:00:00.000Zpositive

  Price move: AMGN rose 3.5%

  AMGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-11T00:00:00.000Zpositive

  Price move: AMGN rose 4.8%

  AMGN 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $381.64 from 22 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-13SellKhosla Rachna(officer: SVP, Business Development)1,252 shares
• 2026-08-11SellKhosla Rachna(officer: SVP, Business Development)2,000 shares
• 2026-08-06SellGrygiel Nancy A.(officer: SVP & CCO)1,000 shares
• 2026-08-06SellMiller Derek(officer: SVP, Human Resources)1,821 shares

US Congress trading disclosures

• 2026-04-07Mark Warner (VA)Sale$1,001 - $15,000
• 2026-04-07Mark Warner (VA)Sale$1,001 - $15,000
• 2026-04-06Mark Warner (VA)Sale$1,001 - $15,000

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。